A structured meal plan for tirzepatide users can help ensure adequate nutrition despite reduced appetite
citeturn2news12 How do I pick the right program
Microdosing GLP-1 Receptor Agonists During Perimenopause: A Clinical Approach to Hormonal Weight Gain Written and edited by Sarah Bonza MD, MPH, FAAFP, MSCP, DipABLM, NBC-HWC Perimenopause represents a challenging time for women, with up to 70% experiencing weight gain due to declining estrogen levels, decreased energy expenditure, and metabolic changes
* Such #comprehensive #care will support #treatment #benefits beyond body weight alone and will make clinicians more effective stewards of GLP-1s and, ultimately, of patients' overall #health
But its still important to confirm that dual agonist drugs like tirzepatide can offer similar or even potentially greater cardiovascular benefits (in theory, it was possible that one of the ingredients could have negatively affected the heart)
But they will be, if history is any indication